Fedratinib

Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.

Retrieved on: 
Monday, April 1, 2024
Research, Pacritinib, JAK2, Bone marrow, Blood transfusion, CXCR4, Inflammation, Patient, University, Ruxolitinib, Clinical trial, CXCL12, Fedratinib, Safety, Pancreatic serous cystadenoma, University of California, Davis, MD Anderson Cancer Center, Albert Einstein Israelite Hospital, Pharmaceutical industry

Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.

Key Points: 
  • Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.
  • This research will be conducted under the guidance of Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute- Mount Sinai.
  • CK0804 is a novel allogeneic, CXCR4 enriched, Treg cell therapy product that utilizes Cellenkos' proprietary CRANE® technology to generate disease specific products.
  • Dr. Ronald Hoffman serves as a paid consultant for Cellenkos.

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer

Retrieved on: 
Tuesday, October 10, 2023
Memorial, Robert Wood Johnson Medical School, Doctor of Philosophy, Rutgers University, Internal medicine, Ipilimumab, Bristol Myers Squibb, Memorial Sloan Kettering Cancer Center, Therapy, Growth, Nivolumab, Harvard Medical School, Beth Israel Deaconess Medical Center, Fedratinib, Spacecraft, ADC, Broad arrow, Hematology, Patient, Pharmaceutical industry, MD

LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "As a seasoned Chief Medical Officer, Dr. Yang's extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company.
  • Dr. Arvin Yang, newly appointed Chief Medical Officer of Pheon Therapeutics, commented: "Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumors.
  • He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology.

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer

Retrieved on: 
Tuesday, October 10, 2023
Memorial, Robert Wood Johnson Medical School, Doctor of Philosophy, Rutgers University, Internal medicine, Ipilimumab, Bristol Myers Squibb, Memorial Sloan Kettering Cancer Center, Therapy, Growth, Nivolumab, Harvard Medical School, Beth Israel Deaconess Medical Center, Fedratinib, Spacecraft, ADC, Broad arrow, Hematology, Patient, Pharmaceutical industry, MD

LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "As a seasoned Chief Medical Officer, Dr. Yang's extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company.
  • Dr. Arvin Yang, newly appointed Chief Medical Officer of Pheon Therapeutics, commented: "Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumors.
  • He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology.

Nine Square Therapeutics Appoints John Hood to Board of Directors

Retrieved on: 
Tuesday, September 13, 2022
Therapy, Fedratinib, Eye disease, ATP, Research, University of California, San Francisco, Neurodegeneration, Idiopathic pulmonary fibrosis, Hope, Parkinson's disease, Growth, Degenerative disease, Ruxolitinib, Patient, Cancer, CEO, Texas A&M University, Bristol Myers Squibb, Founder, Board of directors, Biochemistry, Board, The Seven By Nine Squares, SAN, ALS, Biotechnology, Computational chemistry, University, Drug discovery, Movement disorders, UCSF, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 /PRNewswire/ -- Nine Square Therapeutics, a biotechnology company applying computational chemistry and machine-learning enabled cell profiling to discover and develop novel small-molecule therapeutics for life-threatening neurodegenerative diseases, such as Parkinson's disease and ALS, announced today that John Hood, Ph.D., has joined the company's Board of Directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 /PRNewswire/ -- Nine Square Therapeutics, a biotechnology company applying computational chemistry and machine-learning enabled cell profiling to discover and develop novel small-molecule therapeutics for life-threatening neurodegenerative diseases, such as Parkinson's disease and ALS, announced today that John Hood, Ph.D., has joined the company's Board of Directors.
  • "We are very excited to welcome John to the Nine Square team.
  • In addition, John is an outstanding scientist and drug developer," said Nine Square Therapeutics CEO Robert Paul, M.D.
  • Nine Square Therapeutics is discovering novel small-molecule therapeutics for life-threatening neurodegenerative diseases, such as Parkinson's disease and ALS.

DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

Retrieved on: 
Friday, June 10, 2022
Constellation, Primary myelofibrosis, Fedratinib, Cell, Anemia, Arm, Breathe Me, Fatigue, Ruxolitinib, LinkedIn, Annual report, European Hematology Association, Monocyte, Bleeding, Disease, Blood, Gene, U.S. Securities and Exchange Commission, Physician, BET, Lymphatic system, Weakness, JAK, Patient, Program, Urinary tract infection, Cancer, Risk, Scar, Mount Sinai, EHA, NASDAQ, Judgement, Twitter, Communication, Clinical trial, Cytokine, Industry, FSE, Thrombocytopenia, Bone marrow, Chronic leukemia, TD, Safety, Joint Planning and Development Office, Pharmaceutical industry, Medical imaging, MorphoSys

The latest findings suggest pelabresib may have disease-modifying properties and confirm previous data supporting the potential of pelabresib as a treatment for patients with myelofibrosis.

Key Points: 
  • The latest findings suggest pelabresib may have disease-modifying properties and confirm previous data supporting the potential of pelabresib as a treatment for patients with myelofibrosis.
  • The data are being presented during oral and poster sessions at the European Hematology Association 2022 (EHA 2022) Hybrid Congress being held in Vienna.
  • Additionally, pelabresib alone or in combination decreased pro-inflammatory and pro-fibrotic signaling in monocytes, suggesting a potential attenuation of disease processes.
  • MANIFEST (NCT02158858) is an open-label Phase 2 clinical trial of pelabresib in patients with myelofibrosis.

MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

Retrieved on: 
Friday, June 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Constellation, Primary myelofibrosis, Fedratinib, Cell, Anemia, Arm, Breathe Me, Fatigue, Ruxolitinib, LinkedIn, Annual report, European Hematology Association, Monocyte, Bleeding, Disease, Blood, Gene, U.S. Securities and Exchange Commission, Physician, BET, Lymphatic system, Weakness, JAK, Patient, Program, Urinary tract infection, Cancer, Risk, Scar, Mount Sinai, EHA, NASDAQ, Judgement, Twitter, Communication, Clinical trial, Cytokine, Industry, FSE, Thrombocytopenia, Bone marrow, Chronic leukemia, TD, Safety, Joint Planning and Development Office, Pharmaceutical industry, Medical imaging, MorphoSys

The latest findings suggest pelabresib may have disease-modifying properties and confirm previous data supporting the potential of pelabresib as a treatment for patients with myelofibrosis.

Key Points: 
  • The latest findings suggest pelabresib may have disease-modifying properties and confirm previous data supporting the potential of pelabresib as a treatment for patients with myelofibrosis.
  • The data are being presented during oral and poster sessions at the European Hematology Association 2022 (EHA 2022) Hybrid Congress being held in Vienna.
  • Additionally, pelabresib alone or in combination decreased pro-inflammatory and pro-fibrotic signaling in monocytes, suggesting a potential attenuation of disease processes.
  • MANIFEST (NCT02158858) is an open-label Phase 2 clinical trial of pelabresib in patients with myelofibrosis.

Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib

Retrieved on: 
Monday, June 3, 2019
Health, Biotechnology, Clinical trials, Oncology, Chemical compounds, Chemistry, Organic compounds, Nitriles, Pyrazoles, Cyclopentanes, Ruxolitinib, Pyrimidines, Celgene, Myelofibrosis, Intention-to-treat analysis, Fedratinib

Celgene Corporation (NASDAQ: CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with ruxolitinib.

Key Points: 
  • Celgene Corporation (NASDAQ: CELG) announced an updated analysis of data from the Phase 2 JAKARTA2 clinical study demonstrating clinically meaningful response rates with investigational fedratinib in patients with myelofibrosis previously treated with ruxolitinib.
  • This updated analysis of fedratinib employed intent-to-treat (ITT) principles and utilized a narrower definition of ruxolitinib relapsed, refractory, or intolerant patients.
  • These updated results show meaningful reductions in spleen volume and symptoms and reinforce the potential of fedratinib in these difficult-to-treat patients who no longer receive benefit from ruxolitinib.
  • Fedratinib has the potential to be the first new treatment option since 2011 for patients with myelofibrosis, said Dr. Alise Reicin, President, Global Clinical Development, for Celgene.